| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T87 |
0-227 |
Sentence |
denotes |
Another candidate COVID-19 vaccine for Phase I clinical trial is from the University of Oxford and AstraZeneca (NCT04324606).68 Around 1110 people will take part in the trial, which started recruitment at the end of April 2020. |
| T88 |
228-334 |
Sentence |
denotes |
The vaccine is based on a chimpanzee adenovirus vaccine vector (ChAdOx1) and the SARS-CoV-2 spike protein. |
| T89 |
335-468 |
Sentence |
denotes |
Chimpanzee adenoviral vectors against different pathogens have been already tested in thousands of subjects with demonstrated safety. |
| T90 |
469-567 |
Sentence |
denotes |
To date, ChAdOx1 has been administered to six rhesus macaques exposed to high doses of SARS-CoV-2. |
| T91 |
568-1203 |
Sentence |
denotes |
The vaccine was unable to prevent infections, although it reduced the severity of the disease: no signs of virus replication were observed in the lungs, with significantly lower levels of respiratory disease and no lung damage compared to control animals, according to a recent article deposited in bioRxiv.69 Another adenoviral vector vaccine developed by CanSino Biological Inc. and Beijing Institute of Biotechnology using a genetically engineered replication-defective adenovirus type 5 vector to express the SARS-CoV-2 spike protein (Ad5-nCoV) is currently being tested in Phase I/II trials (NCT04398147, NCT04341389, NCT0431312). |
